SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTSecond Amendment • August 8th, 2018 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This Second Amendment (“Second Amendment”) is entered into as of June 5, 2018 (the “Second Amendment Effective Date”), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O’Brien Drive, Menlo Park, CA 94025 (“Adverum”), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 (“Editas”), and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas, as amended by that certain Amendment to Collaboration, Option and License Agreement, dated January 25, 2018 (the “Agreement”). Adverum and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
SUMMARY OF BASIC LEASE INFORMATIONSeaport Center • August 8th, 2018 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
